The Q3 beat was driven by extraordinary demand for molecular-based COVID-19 tests and a sequential recovery in the ex-COVID business. Geographically, North America led from the front and Europe witnessed acceleration. The EBITDA margin expanded, benefiting from operational leverage. Given the increasing production capacity of molecular tests and the recent launch of an antigen COVID-19 test, Q4 is likely to be another strong quarter. Management anticipates high demand for COVID-19 tests for FY21 ....
12 Nov 2020
Exceptional demand for molecular COVID-19 tests in Q3
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Exceptional demand for molecular COVID-19 tests in Q3
The Q3 beat was driven by extraordinary demand for molecular-based COVID-19 tests and a sequential recovery in the ex-COVID business. Geographically, North America led from the front and Europe witnessed acceleration. The EBITDA margin expanded, benefiting from operational leverage. Given the increasing production capacity of molecular tests and the recent launch of an antigen COVID-19 test, Q4 is likely to be another strong quarter. Management anticipates high demand for COVID-19 tests for FY21 ....